FLT3 and acute myeloid leukemia: The efficacy of PKC412 in combination with standard chemotherapy lead to that the US Food and Drug Administration (FDA) in 2017 approved PKC412 (Rydapt, Novartis Pharmaceuticals, Inc) for treatment of patients with newly diagnosed FLT3-mutated AML and is the first drug to receive regulatory approval for AML since year 2000 in the United States [11].